source
- Abivax shares surge as worries subside over immune drug’s cancer riskAccording to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.BioPharma Dive · 1mo ago↗ source
- Ipsen to scoop up Memo Therapeutics and its kidney infection drugIpsen is on an M&A roll. The French drugmaker announced its second deal of the week, saying it would buy Memo Therapeutics and its drug candidate called potravitug for a viral ...Endpoints · 1mo ago↗ source
- A June flourish lifts biotech megaround tally in first half of 2026Forty private biotech companies disclosed funding rounds of $100 million or more in the first half of 2026, according to an Endpoints News tally. That's more than the same period of 2025 ...